VivoSeq
Metabolic & Endocrine

Tophaceous Gout

0

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Tophaceous Gout is an early-stage landscape with 0 programs across 2 companies. The most active players are Crystalys Therapeutics, Ardea Biosciences, Inc..

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Crystalys Therapeutics

0 programs

PreclinicalA

Ardea Biosciences, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

2

clinical trials

Recruiting1 · 50%
Completed1 · 50%

Clinical Trials

Trial Activity

A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
Recruiting·CCrystalys Therapeutics·Phase 3·NCT07089888·250 enrolled
Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat
Completed·AArdea Biosciences, Inc.·Phase 3·NCT01510769·330 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)